When EGFR meets MET: Dual blockade as the next post-TKI standard?
1/5 보강
The SACHI trial demonstrated that savolitinib plus osimertinib nearly doubled progression-free survival (PFS) compared with chemotherapy (9.8 vs.
APA
Arter ZL, Soo RA (2026). When EGFR meets MET: Dual blockade as the next post-TKI standard?. Med (New York, N.Y.), 7(3), 101062. https://doi.org/10.1016/j.medj.2026.101062
MLA
Arter ZL, et al.. "When EGFR meets MET: Dual blockade as the next post-TKI standard?." Med (New York, N.Y.), vol. 7, no. 3, 2026, pp. 101062.
PMID
41831430
Abstract
The SACHI trial demonstrated that savolitinib plus osimertinib nearly doubled progression-free survival (PFS) compared with chemotherapy (9.8 vs. 5.4 months; hazard ratio 0.34) in patients with EGFR-mutated, MET-amplified non-small-cell lung cancer (NSCLC) after EGFR tyrosine kinase inhibitor (TKI) failure-the first phase 3 evidence for dual EGFR/MET inhibition in this setting..